Document Detail

Corticosteroid rescue treatment of progressive fibroproliferation in late ARDS. Patterns of response and predictors of outcome.
MedLine Citation:
PMID:  8181346     Owner:  NLM     Status:  MEDLINE    
Pulmonary fibroproliferation (PFP) is directly or indirectly the leading cause of death in patients with late ARDS. We previously reported our experience using intravenous corticosteroids (IVC) in 8 patients with late ARDS and now have expanded our observation to a total of 25 patients with severe fibroproliferation (mean lung injury score [LIS] 3) and progressive respiratory failure (RF). Thirteen patients had open-lung biopsy before treatment. Patients were started on IVC treatment (IVCT) an average of 15 +/- 7.5 days into mechanical ventilation (MV). Significant physiologic improvement (SPI) to IVCT was defined as a reduction in LIS of greater than 1 point or an increase in PaO2:FIO2 ratio of greater than 100. We observed three patterns of response: rapid responders (RR) had an SPI by day 7 (n = 15); delayed responders (DR) had an SPI by day 14 (n = 6); nonresponders (NR) were without SPI by day 14 (n = 4). Overall the following significant mean changes were seen within 7 days of IVCT: LIS from 3 to 2 (p = 0.001), PaO2:FIO2 from 162 to 234 (p = 0.0004), PEEP from 11 to 6.8 cm H2O (p = 0.001), chest radiograph score from 3.8 to 3.0 (p = 0.009), and VE from 16 to 13.6 L/min (p = 0.01). Development of pneumonia was related to the pattern of response. Surveillance bronchoscopy was effective in identifying pneumonia in eight afebrile patients. Nineteen of 25 (76 percent) patients survived the ICU admission. Comparisons were made between survivors (S) and nonsurvivors (NS) and among the three groups of responders. At the time ARDS developed, no physiologic or demographic variable could discriminate between S and NS. At the time of IVCT, only liver failure was more frequent in nonsurvivors (p = 0.035). Histologic findings at open-lung biopsy and pattern of physiologic response clearly predicted outcome. The presence of preserved alveolar architecture (p = 0.045), myxoid type fibrosis (p = 0.045), coexistent intraluminal bronchiolar fibrosis (p = 0.0045), and lack of arteriolar subintimal fibroproliferation (p = 0.045) separated S from NS. ICU survival rate was 86 percent in responders and 25 percent in nonresponders (p = 0.03). Only one death resulted from refractory respiratory failure.
G U Meduri; A J Chinn; K V Leeper; R G Wunderink; E Tolley; H T Winer-Muram; V Khare; M Eltorky
Related Documents :
24861986 - No exacerbation of perihematomal edema with intraclot urokinase in patients with sponta...
16365336 - Early goal-directed therapy, corticosteroid, and recombinant human activated protein c ...
20052456 - Noninvasive and invasive ventilation in acute respiratory failure associated with bronc...
19108006 - Non-invasive ventilation for treatment of postoperative respiratory failure after oesop...
3941126 - The long-term results of the liverpool mark ii knee prosthesis.
19298406 - Prospective comparison of five mediators of the systemic response after high-intensity ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Chest     Volume:  105     ISSN:  0012-3692     ISO Abbreviation:  Chest     Publication Date:  1994 May 
Date Detail:
Created Date:  1994-06-15     Completed Date:  1994-06-15     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0231335     Medline TA:  Chest     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1516-27     Citation Subset:  AIM; IM    
Pulmonary and Critical Care Division, University of Tennessee Medical Center, Regional Medical Center, Memphis.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Combined Modality Therapy
Infusions, Intravenous
Injections, Intravenous
Lung / pathology*
Methylprednisolone Hemisuccinate / administration & dosage*
Middle Aged
Respiration, Artificial
Respiratory Distress Syndrome, Adult / drug therapy*,  pathology,  physiopathology,  therapy
Salvage Therapy
Reg. No./Substance:
2921-57-5/Methylprednisolone Hemisuccinate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Nebulized ipratropium bromide in ventilator-assisted patients with chronic bronchitis.
Next Document:  Preservation of pulmonary function by an outer membrane protein F vaccine. A study in rats with chro...